Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 20, 2024

BUY
$2.8 - $5.46 $1,761 - $3,434
629 New
629 $1,000
Q1 2023

Apr 25, 2023

SELL
$2.8 - $5.46 $1,167 - $2,276
-417 Reduced 39.87%
629 $1,000
Q4 2022

Feb 03, 2023

BUY
$2.85 - $5.18 $2,664 - $4,843
935 Added 842.34%
1,046 $3,000
Q3 2022

Nov 10, 2022

BUY
$2.85 - $8.73 $316 - $969
111 New
111 $0
Q2 2022

Aug 01, 2022

SELL
$4.69 - $9.84 $975 - $2,046
-208 Closed
0 $0
Q1 2022

Apr 28, 2022

SELL
$8.44 - $16.89 $903 - $1,807
-107 Reduced 33.97%
208 $2,000
Q4 2021

Jan 20, 2022

BUY
$14.7 - $19.89 $1,572 - $2,128
107 Added 51.44%
315 $5,000
Q2 2020

Jul 16, 2020

BUY
$7.53 - $14.93 $1,566 - $3,105
208 New
208 $3,000
Q1 2020

Apr 27, 2020

SELL
$5.69 - $17.78 $301 - $942
-53 Closed
0 $0
Q4 2019

Jan 30, 2020

BUY
$10.89 - $16.79 $577 - $889
53 New
53 $1,000

Others Institutions Holding ATRA

About Atara Biotherapeutics, Inc.


  • Ticker ATRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,362,304
  • Market Cap $1.08B
  • Description
  • Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...
More about ATRA
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.